Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix?

Gynecologic Oncology

Volumn 106, Issue 2, 2007, Pages 394-399

  Cerciello, Ferdinando ^a   Riesterer, Oliver ^a   Sherweif, Mohamed ^b   Odermatt, Bernhard ^a   Ciernik, I Frank ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Cancer; Carcinoma; Carcinoma of the uterine cervix; Cervix; Chemoradiation; Combined modality treatment; EGFR; Epidermal growth factor; Epidermal growth factor receptor; Predictive factors; Radiation therapy; Radiotherapy; Tyrosin kinase receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DENSITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA;

ADULT; APOPTOSIS; CDC2 PROTEIN KINASE; CELL CYCLE; CYCLIN B; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 34447636969     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.04.019     Document Type: Article

References (34)

1. Rose P.G. Combined-modality therapy of locally advanced cervical cancer. J. Clin. Oncol. 21 (2003) 211-217
2. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 (1999) 1137-1143
3. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl 4 (2001) S9-S15
4. Lee C.M., Lee R.J., Hammond E., et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol. Oncol. 93 (2004) 209-214
5. Tangjitgamol S., Ramirez P.T., Sun C.C., et al. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int. J. Gynecol. Cancer 15 (2005) 646-656
6. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11 (2004) 689-708
7. Schmidt M., and Lichtner R.B. EGF receptor targeting in therapy-resistant human tumors. Drug Resist. Updat. 5 (2002) 11-18
8. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol. Biol. Cell 10 (1999) 2493-2506
9. Harari P.M., and Huang S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 427-433
10. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8 (2002) 3250-3258
11. Milas L., Fan Z., Andratschke N.H., et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 966-971
12. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59 (1999) 1935-1940
13. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6 (2000) 2166-2174
14. Ang K.K., Andratschke N.H., and Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 959-965
15. Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 21-26
16. Solomon B., Hagekyriakou J., Trivett M.K., et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 713-723
17. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
18. Farley J, Schilder R. Phase I study of cetuximab in combination with cisplatin, external beam radiotherapy, and brachytherapy in patients with stage ib-iva cervical cancer. http://www.cancer.gov/clinicaltrials/GOG-9918.
19. Fracasso PM. Cetuximab, cisplatin, and radiotherapy in women with locally advanced cervical carcinoma, phase II trial. http://clinicaltrials.gov/show/NCT00292955.
20. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62 (2002) 7350-7356
21. Eriksen J.G., Buffa F.M., Alsner J., et al. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother. Oncol. 72 (2004) 275-282
22. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J. Clin. Oncol. 23 (2005) 5560-5567
23. Pillai M.R., Jayaprakash P.G., and Nair M.K. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J. Cancer Res. Clin. Oncol. 124 (1998) 456-461
24. Eriksen J.G., Steiniche T., Askaa J., et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 561-566
25. Eriksen J.G., Steiniche T., and Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother. Oncol. 74 (2005) 93-100
26. Han S.W., Hwang P.G., Chung D.H., et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int. J. Cancer 113 (2005) 109-115
27. Oka K., Nakano T., and Arai T. c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 73 (1994) 664-671
28. Vaidya A.P., Parnes A.D., and Seiden M.V. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Curr. Treatm. Opt. Oncol. 6 (2005) 103-114
29. Gaffney D.K., Haslam D., Tsodikov A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 922-928
30. Eicheler W., Krause M., Hessel F., et al. Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother. Oncol. 76 (2005) 151-156
31. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. 72 (2004) 257-266
32. Cerciello F., Hofstetter B., Fatah S.A., et al. G2/M cell cycle checkpoint is functional in cervical cancer patients after initiation of external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1390-1398
33. Hofstetter B., Vuong V., Broggini-Tenzer A., et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin. Cancer Res. 11 (2005) 1588-1596
34. Ang KK. Radiation therapy and cisplatin with or without cetuximab in treating patients with stage III or stage IV head and neck cancer. (trial RTOG-0522). http://clinicaltrials.gov/ct/show/NCT00265941.